Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Almirid
2. Cripar
3. Dihydroergocryptine Mesylate
4. Dihydroergocryptine Monomesylate
5. Dihydroergokryptine Mesylate
6. Dihydroergokryptine Monomesylate
7. Mesylate, Dihydroergocryptine
8. Mesylate, Dihydroergokryptine
9. Monomesylate, Dihydroergocryptine
10. Monomesylate, Dihydroergokryptine
1. Dihydro-alpha-ergocryptine
2. 25447-66-9
3. Alpha-dihydroergocryptine
4. 9,10-dihydro-alpha-ergocryptine
5. Alpha-dihydroergocriptine
6. 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-9,10alpha-dihydroergotaman-3',6',18-trione
7. Chembl1743263
8. Chebi:59919
9. 202229ir8y
10. Dihydroergocriptine
11. (10alphah)-12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)-9,10-dihydroergotaman
12. (6ar,9r,10ar)-n-[(1s,2s,4r,7s)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide
13. 9,10-dihydroergocryptine
14. Einecs 246-993-6
15. Dihydro-.alpha.-ergocryptine
16. Unii-202229ir8y
17. Ncgc00183332-01
18. Dsstox_cid_28615
19. Dsstox_rid_82885
20. Dsstox_gsid_48689
21. Schembl233373
22. Dtxsid5048689
23. Bdbm81453
24. Zinc3929793
25. Tox21_113078
26. Bdbm50390994
27. Pdsp2_001088
28. Cas_159729
29. Db11274
30. Nsc_159729
31. Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.,10.alpha.)-
32. Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha,10alpha)-
33. Cas-25447-66-9
34. D07835
35. Q905717
36. (6ar,9r,10ar)-n-[(1s,2r,4r,7s)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide
37. 12'-hydroxy-2'-(1-methylethyl)-5'.alpha.-(2-methylpropyl)-9,10.alpha.-dihydroergotaman-3',6',18-trione
| Molecular Weight | 577.7 g/mol |
|---|---|
| Molecular Formula | C32H43N5O5 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 577.32641949 g/mol |
| Monoisotopic Mass | 577.32641949 g/mol |
| Topological Polar Surface Area | 118 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 1130 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Alpha-dihydroergocryptine has been studied for the early treatment of Parkinson disease as well as for its use in migraine prophylaxis, treatment of low blood pressure and peripheral vascular disorder. To know more about the ergoloid mesylate mixture and its uses please visit [DB01049].
The effect of alpha-dihydroergocryptine in dopamine receptors was tested in PD patients and seem to generate a significant clinical improvement in the tested patients as well as to reduce motor complications and side effects. In long-term clinical trials with Parkinson disease patients, the administration of alpha-dihydroergocryptine and levodopa, the symptoms were reposted to improve or completely vanish in 80% of the tested individuals. All the registered effects of alpha-dihydroergocryptine suggest a potential neuroprotective effect of this drug and some reports have indicated that this activity may be related to the activation of NF-kB. The effect of alpha-dihydroergocryptine in the dopamine D2 receptor also reduces prolactin plasma levels and induce hypotension. To know more about the ergoloid mesylate mixture please visit [DB01049].
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Absorption
Alpha-dihydroergocryptine is rapidly absorbed but it presents a very low bioavailability as it is part of a first-pass hepatic metabolism and thus less of 5% of the administered dose reaches blood circulation. The peak plasma concentration is attained after 30-120 minutes. The absorption of alpha-dihydroergocryptine is not affected by the co-administration with food. When administered in repeated oral doses the Cmax after 1 hour was registered to be 2157 pg/ml. To know more about the ergoloid mesylate mixture please visit [DB01049].
Route of Elimination
Alpha-dihydroergocryptine is eliminated mainly by feces and to present a very low urinary excretion. To know more about the ergoloid mesylate mixture please visit [DB01049].
Volume of Distribution
In preclinical studies, the volume of distribution after intravenous or oral administration was registered to be 11.054 L and 218.630 L respectively. To know more about the ergoloid mesylate mixture please visit [DB01049].
Clearance
In preclinical studies, the clearance rate after intravenous or oral administration was registered to be 1.129 L/h and 25.98 L/h respectively. To know more about the ergoloid mesylate mixture please visit [DB01049].
Alpha-dihydroergocryptine presents a linear metabolism with the formation of active metabolites and the metabolism kinetics of this compound has no interference with L-dopa. It is highly metabolized with a rate of 2.4 ng/min/mg protein in the microsomal system and a formation of eight different metabolites. the metabolism of alpha-dihydroergocryptine seems to be highly marked by the action of CYP 3A4. To know more about the ergoloid mesylate mixture please visit [DB01049].
Alpha-dihydroergocryptine has been studied in Parkinson disease models and it has shown a half-life of 12-16 hours. To know more about the ergoloid mesylate mixture please visit [DB01049].
Alpha-dihydroergocryptine is an established high-affinity ligand to alpha 1 and alpha 2 adrenoreceptors in a number of tissues as well as a dopamine ligand in the brain. It is reported to be a potent agonist of the dopamine D2 receptor and a partial agonist of the dopamine receptors D1 and D3. To know more about the ergoloid mesylate mixture please visit [DB01049] and to know more about the isomer please visit [DB11275].
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Chewable & Orodispersible Aids
Co-Processed Excipients
Taste Masking
Coating Systems & Additives
Film Formers & Plasticizers
Granulation
Disintegrants & Superdisintegrants
Lubricants & Glidants
Thickeners and Stabilizers
Controlled & Modified Release
Parenteral
API Stability Enhancers
Topical
Global Sales Information
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
